[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2024, "totalPay": 254846, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "President", "fiscalYear": 2024, "totalPay": 485459, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Mailling", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 209224, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hamed  Ghanei", "title": "Chief Business Officer", "fiscalYear": 2024, "totalPay": 58433, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shengnan  Guo", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.8, "open": 9.9, "dayLow": 9.9, "dayHigh": 11.42, "regularMarketPreviousClose": 9.8, "regularMarketOpen": 9.9, "regularMarketDayLow": 9.9, "regularMarketDayHigh": 11.42, "payoutRatio": 0.0, "beta": 0.513, "trailingPE": 31.583332, "forwardPE": 22.74, "volume": 25290, "regularMarketVolume": 25290, "averageVolume": 9504, "averageVolume10days": 13570, "averageDailyVolume10Day": 13570, "bid": 11.15, "ask": 11.19, "bidSize": 3800, "askSize": 3700, "marketCap": 291332384, "fiftyTwoWeekLow": 6.63, "fiftyTwoWeekHigh": 14.6, "priceToSalesTrailing12Months": 6.121457, "fiftyDayAverage": 9.367, "twoHundredDayAverage": 9.5014, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 302843584, "profitMargins": 0.25517, "floatShares": 5164338, "sharesOutstanding": 25622900, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42384997, "heldPercentInstitutions": 0.01342, "shortRatio": 0.97, "impliedSharesOutstanding": 25763800, "bookValue": 4.31, "priceToBook": 2.638051, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": 0.968, "netIncomeToCommon": 12144000, "trailingEps": 0.36, "forwardEps": 0.5, "enterpriseToRevenue": 6.363, "enterpriseToEbitda": 18.288, "52WeekChange": 0.16615379, "SandP52WeekChange": 0.19554341, "quoteType": "EQUITY", "currentPrice": 11.37, "recommendationMean": 1.75, "recommendationKey": "buy", "totalCash": 11339000, "totalCashPerShare": 0.447, "ebitda": 16560000, "totalDebt": 25455000, "quickRatio": 1.306, "currentRatio": 1.72, "totalRevenue": 47592000, "debtToEquity": 23.26, "revenuePerShare": 1.867, "returnOnAssets": 0.04907, "returnOnEquity": 0.12252, "grossProfits": 35116000, "freeCashflow": -66023752, "operatingCashflow": 21127000, "earningsGrowth": 0.833, "revenueGrowth": 1.523, "grossMargins": 0.73786, "ebitdaMargins": 0.34796003, "operatingMargins": 0.37299, "financialCurrency": "USD", "symbol": "CPHRF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "marketState": "CLOSED", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1138890600000, "regularMarketChange": 1.5699997, "regularMarketDayRange": "9.9 - 11.42", "fullExchangeName": "OTC Markets OTCQX", "averageDailyVolume3Month": 9504, "fiftyTwoWeekLowChange": 4.74, "fiftyTwoWeekLowChangePercent": 0.7149321, "fiftyTwoWeekRange": "6.63 - 14.6", "fiftyTwoWeekHighChange": -3.2300005, "fiftyTwoWeekHighChangePercent": -0.2212329, "fiftyTwoWeekChangePercent": 16.61538, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "earningsCallTimestampStart": 1746793800, "earningsCallTimestampEnd": 1746793800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.36, "epsForward": 0.5, "fiftyDayAverageChange": 2.0030003, "fiftyDayAverageChangePercent": 0.21383584, "twoHundredDayAverageChange": 1.8685999, "twoHundredDayAverageChangePercent": 0.19666575, "corporateActions": [], "regularMarketTime": 1754611200, "exchange": "OQX", "messageBoardId": "finmb_8201659", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "shortName": "Cipher Pharmaceuticals, Inc.", "longName": "Cipher Pharmaceuticals Inc.", "regularMarketChangePercent": 16.020405, "regularMarketPrice": 11.37, "displayName": "Cipher Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-09"}]